Published in Bull Cancer on February 01, 2011
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol (2010) 1.43
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene (2005) 1.27
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer (2003) 1.24
P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer (2005) 1.23
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer (2010) 1.16
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res (2006) 1.12
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00
Detecting single DNA copy number variations in complex genomes using one nanogram of starting DNA and BAC-array CGH. Nucleic Acids Res (2004) 1.00
The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J Cell Sci (2005) 0.99
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs (2010) 0.95
Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J Clin Invest (2010) 0.94
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94
A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res (2011) 0.92
ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma. Clin Chem (2006) 0.92
p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res (2008) 0.92
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood (2002) 0.90
Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line. J Cell Sci (2004) 0.89
Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol (2011) 0.89
Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev (2011) 0.88
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin Chem (2012) 0.88
Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88
WNT5A encodes two isoforms with distinct functions in cancers. PLoS One (2013) 0.87
DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol (2002) 0.87
Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res (2010) 0.86
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations. Cancer Res (2004) 0.86
MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol (2003) 0.86
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer (2011) 0.86
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85
Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors. Cancer Genet Cytogenet (2004) 0.85
Down's syndrome protects against breast cancer: is a constitutional cell microenvironment the key? Int J Cancer (2005) 0.85
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer (2012) 0.85
p21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma. BMC Cancer (2010) 0.84
Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells. Int J Oncol (2006) 0.84
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84
Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma. BMC Cancer (2009) 0.83
Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol (2005) 0.83
ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. Eur J Hum Genet (2011) 0.83
Wnt-5a gene expression in malignant human neuroblasts. Cancer Lett (2005) 0.83
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2015) 0.83
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Invest New Drugs (2011) 0.83
Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genet Cytogenet (2003) 0.82
Changing therapeutic paradigms in castrate-resistant prostate cancer. Clin Genitourin Cancer (2010) 0.81
Expression of p53-family members and associated target molecules in breast cancer cell lines in response to vincristine treatment. Biochem Pharmacol (2002) 0.81
QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol (2009) 0.81
Carcinogenesis in Down syndrome: what can be learned from trisomy 21? Semin Cancer Biol (2008) 0.80
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs (2009) 0.80
Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. Curr Opin Oncol (2014) 0.79
Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant. Mol Cancer Ther (2012) 0.79
Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Cell Cycle (2008) 0.79
Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients. Cancer Med (2014) 0.79
Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol (2012) 0.79
Targeted therapies in metastatic renal cell carcinoma: overview of the past year. Curr Urol Rep (2012) 0.78
Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas. Clin Cancer Res (2005) 0.78
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Invest New Drugs (2010) 0.78
Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol (2009) 0.78
A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol (2011) 0.78
Delivery by shock waves of active principle embedded in gelatin-based capsules. Ultrason Sonochem (2007) 0.77
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Invest New Drugs (2013) 0.77
Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients? Am J Clin Oncol (2012) 0.77
[Locally advanced prostate cancer: definition, prognosis and treatment]. Bull Cancer (2007) 0.77
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs (2010) 0.77
Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Clin Genitourin Cancer (2012) 0.77
[A new view on p53 protein cytoplasmic sequestration]. Bull Cancer (2003) 0.76
MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. J Pathol (2002) 0.76
When p53 needs p73 to be functional - forced p73 expression induces nuclear accumulation of endogenous p53 protein. Cancer Lett (2003) 0.76
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials. Onkologie (2013) 0.76
[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2012) 0.76
[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2011) 0.76
New agents in metastatic prostate cancer. Eur J Cancer (2009) 0.76
Toward a better dialogue between neuro-oncologists and phase I investigators. J Clin Oncol (2012) 0.75
[Metastatic potential: a generic characteristic of the primary tumor]. Bull Cancer (2004) 0.75
[Interrelations between p73 and p53: a model, neuroblastoma]. Med Sci (Paris) (2004) 0.75
Wound healing delay after central venous access following DCF/VEGF-trap therapy. Invest New Drugs (2009) 0.75
[Predicting metastatic potential: genetic markers]. Med Sci (Paris) (2003) 0.75
[New hope in the treatment of advanced cancer of the prostate in 2012]. Bull Cancer (2012) 0.75